Oryzon Genomics - First patient dosed in new AML combination study
Oryzon Genomics has announced the commencement of patient dosing in the investigator-initiated Phase Ib trial evaluating iadademstat as a...
415 Views
Oryzon Genomics - Multiple milestones anticipated in H224
Oryzon’s Q224 results summarised an active quarter for its clinical pipeline, with multiple milestones expected in H224. Central to the H224...
283 Views
Oryzon Genomics - Strengthening vafidemstat’s IP profile
Oryzon Genomics continues to fortify its IP profile for vafidemstat, which is being developed for borderline personality disorder (BPD) and for the...
196 Views
Oryzon Genomics - Encouraging interim update on FRIDA
Oryzon Genomics has reported positive interim data from the Phase Ib FRIDA study, evaluating iadademstat in combination with gilteritinib in...
323 Views
Oryzon Genomics - ALICE data published in The Lancet Haematology
Oryzon Genomics has announced the publication of the final ALICE trial results in the recognised peer-reviewed journal The Lancet Haematology. The...
318 Views